ERYP Erytech Pharma S.A.

5.92
+0.33  (+6%)
Previous Close 5.59
Open 5.71
52 Week Low 4.1
52 Week High 13
Market Cap $164,141,158
Shares 27,726,547
Float 27,726,547
Enterprise Value $133,416,775
Volume 26,754
Av. Daily Volume 1,401,359
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
GRASPA (Eryaspase)
Acute lymphoblastic leukemia (ALL)
BLA Filing
BLA Filing
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
GRASPA (Eryaspase) - (Trybeca-1)
Pancreatic cancer
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
GRASPA (Eryaspase) - TRYbeCA2
Triple-Negative Breast Cancer (TNBC)
Phase 2/3
Phase 2/3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
GRASPA (Eryaspase) in combination with FOLFIRINOX
Pancreatic cancer
Phase 1
Phase 1
Phase 1 completion of first dose announced April 19, 2021.
Hydro-Lido
Hemorrhoids
Phase 2a
Phase 2a
Phase 2 trial completed.

Latest News


  1. ERYTECH to Host on September 21, 2021
    Second Quarter 2021 conference call and Business Update


    Lyon (France) and Cambridge, MA (U.S.), September 15, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2021 conference call and webcast on Tuesday, September 21, 2021, at 2:30 PM CEST/8:30 AM ET to discuss operational highlights.


    The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/6866536 (Conference ID : 6866536)
    Once registered, participants will receive a unique access code and the call…



    ERYTECH to Host on September 21, 2021

    Second Quarter 2021 conference call and Business Update


    Lyon (France) and Cambridge, MA (U.S.), September 15, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2021 conference call and webcast on Tuesday, September 21, 2021, at 2:30 PM CEST/8:30 AM ET to discuss operational highlights.



    The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/6866536 (Conference ID : 6866536)

    Once registered, participants will receive a unique access code and the call number details to join the teleconference.

    The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/z2wjhmw4.

    An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 6866536#.

    An archive of the webcast will be available on ERYTECH's website, under the "Investors" section at investors.erytech.com



    About ERYTECH

    ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

    The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells' altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out final results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

    ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

    ERYTECH is listed on the Nasdaq Global Select Market in the United States (NASDAQ:ERYP) and on the Euronext regulated market in Paris ((ISIN code: FR0011471135, NASDAQ:ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.        



    For more information, please visit www.erytech.com        

    CONTACTS

      

    ERYTECH                     

    Eric Soyer

    CFO & COO
    LifeSci Advisors, LLC

    Corey Davis, Ph.D.

    Investor Relations



    NewCap

    Mathilde Bohin / Louis-Victor Delouvrier

    Investor relations

    Nicolas Merigeau

    Media relations




    +33 4 78 74 44 38

    investors@ERYTECH.com




    +1 (212) 915 - 2577

    cdavis@lifesciadvisors.com




    +33 1 44 71 94 94

    ERYTECH@newcap.eu



    Attachment



    Primary Logo

    View Full Article Hide Full Article

  2. ERYTECH to Present at the H.C. Wainwright
    23rd Annual Global Investment Conference


    Cambridge, MA (U.S.) and Lyon (France), September 6, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its CEO, Gil Beyen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The Conference will be held virtually with all participants joining remotely from September 13th - 15th, 2021.  

    On-demand Corporate Presentation
    An on-demand corporate presentation will be accessible to conference attendees starting on Monday, September 13th 2021 at 7am ET for 90 days after the event…



    ERYTECH to Present at the H.C. Wainwright

    23rd Annual Global Investment Conference


    Cambridge, MA (U.S.) and Lyon (France), September 6, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its CEO, Gil Beyen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The Conference will be held virtually with all participants joining remotely from September 13th - 15th, 2021.  

    On-demand Corporate Presentation

    An on-demand corporate presentation will be accessible to conference attendees starting on Monday, September 13th 2021 at 7am ET for 90 days after the event. Management will conduct one-on-one meetings with investors during the conference.

    Those interested in registering for the conference can do so here: https://journey.ct.events/view/3f91f4d2-ca26-4e15-86ac-a01567416fbe

    1x1 Meetings

    Gil Beyen, Chief Executive Officer, Iman El-Hariry, Chief Medical Officer and Eric Soyer Chief Financial Officer will participate in one-on-one meetings on September 13th & 14th, 2021.

    For more information about the 23rd Annual Global Investment Conference, please visit the H.C. Wainwright conference website https://hcwevents.com/annualconference/

    If you are interested in arranging a one-on-one meeting, please contact your H.C. Wainwright representative.

    About ERYTECH and eryaspase

    ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

    The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells' altered asparagine and glutamine metabolism. Eryaspase is in a Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out final results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial (IST) in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

    Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and treatment of acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase). The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

    ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

    ERYTECH is listed on the Nasdaq Global Select Market in the United States (NASDAQ:ERYP) and on the Euronext regulated market in Paris ((ISIN code: FR0011471135, NASDAQ:ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.        

    For more information, please visit www.erytech.com        

    CONTACTS



    ERYTECH                     

    Eric Soyer

    CFO & COO
    LifeSci Advisors, LLC

    Corey Davis, Ph.D.

    Investor relations



    NewCap

    Mathilde Bohin / Louis-Victor Delouvrier

    Investor relations

    Nicolas Merigeau

    Media relations




    +33 4 78 74 44 38

    investors@erytech.com




    +1 (212) 915 2577

    cdavis@lifesciadvisors.com




    +33 1 44 71 94 94

    erytech@newcap.eu



    Attachment



    Primary Logo

    View Full Article Hide Full Article

  3. ERYTECH to Participate
    in the Citi 16th Annual BioPharma Conference


    Cambridge, MA (U.S.) and Lyon (France), August 30, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its participation in the Citi 16th Annual BioPharma Conference and invites investors to join virtually via one-on-one meetings.

    Citi's 16th Annual BioPharma Conference– September 8 -10, 2021

    Gil Beyen, Chief Executive Officer, Eric Soyer Chief Financial Officer and Dr. Iman El-Hariry, Chief Medical Officer, will participate in one-on-one meetings on Wednesday September 8th through Friday September 10th.

    If you are interested



    ERYTECH to Participate

    in the Citi 16th Annual BioPharma Conference


    Cambridge, MA (U.S.) and Lyon (France), August 30, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its participation in the Citi 16th Annual BioPharma Conference and invites investors to join virtually via one-on-one meetings.

    Citi's 16th Annual BioPharma Conference– September 8 -10, 2021



    Gil Beyen, Chief Executive Officer, Eric Soyer Chief Financial Officer and Dr. Iman El-Hariry, Chief Medical Officer, will participate in one-on-one meetings on Wednesday September 8th through Friday September 10th.

    If you are interested in arranging a one-on-one meeting, please contact your Citigroup representative. For more information about the Citi 16th Annual BioPharma Conference, please refer to the Citi conference website http://citiconferences.com/other.php.

    About ERYTECH and eryaspase

    ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

    The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells' altered asparagine and glutamine metabolism. Eryaspase is in a Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out final results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial (IST) in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

    Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and treatment of acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase). The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

    ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

    ERYTECH is listed on the Nasdaq Global Select Market in the United States (NASDAQ:ERYP) and on the Euronext regulated market in Paris ((ISIN code: FR0011471135, NASDAQ:ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.        

    For more information, please visit www.erytech.com        

    CONTACTS

    ERYTECH                     

    Eric Soyer

    CFO & COO
    LifeSci Advisors, LLC

    Corey Davis, Ph.D.

    Investor relations



    NewCap

    Mathilde Bohin / Louis-Victor Delouvrier

    Investor relations

    Nicolas Merigeau

    Media relations




    +33 4 78 74 44 38

    investors@erytech.com




    +1 (212) 915 2577

    cdavis@lifesciadvisors.com




    +33 1 44 71 94 94

    erytech@newcap.eu





    Attachment



    Primary Logo

    View Full Article Hide Full Article
  4. ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer

    Webinar on Wednesday, September 1st @ 10am ET/4pm CET


    Cambridge, MA (U.S.) and Lyon (France), August 24, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company, leader in red blood-cell based cancer therapeutics, announced today it will host a key opinion leader webinar on its lead product candidate eryaspase, L-asparaginase encapsulated in donor-derived red blood cells, on Wednesday, September 1, 2021 at 10:00am Eastern Time. The webinar will feature a presentation by KOLs and also the Principal Investigators of the TRYbeCA-1 and rESPECT studies, respectively; Dr. Manuel Hidalgo Medina, M.D., Ph.D., Weill Cornell Medicine/NewYork

    ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer

    Webinar on Wednesday, September 1st @ 10am ET/4pm CET


    Cambridge, MA (U.S.) and Lyon (France), August 24, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company, leader in red blood-cell based cancer therapeutics, announced today it will host a key opinion leader webinar on its lead product candidate eryaspase, L-asparaginase encapsulated in donor-derived red blood cells, on Wednesday, September 1, 2021 at 10:00am Eastern Time. The webinar will feature a presentation by KOLs and also the Principal Investigators of the TRYbeCA-1 and rESPECT studies, respectively; Dr. Manuel Hidalgo Medina, M.D., Ph.D., Weill Cornell Medicine/NewYork-Presbyterian Hospital, and Dr. Marcus Noel, M.D., Georgetown University.

    Dr. Hidalgo will discuss ERYTECH's lead product candidate eryaspase, L-asparaginase encapsulated inside donor-derived red blood cells, in the ongoing Phase 3 TRYbeCA-1 trial which has completed enrollment of 512 second-line metastatic pancreatic cancer patients at approximately 90 clinical sites in Europe and the United States. The TRYbeCA-1 trial is expected to read out final results in Q4 2021. Additionally, Dr. Hidalgo will discuss the medical need and treatment options in second-line pancreatic cancer and speak on his hopes and expectations for the data read out in Q4 2021.

    Dr. Noel will then discuss the view of evaluating eryaspase beyond the second-line setting. Currently, Dr. Noel is conducting in the United States an investigator sponsored Phase 1 dose-escalation trial (rESPECT) with eryaspase in combination with standard chemotherapy as part of first-line treatment for locally advanced and metastatic pancreatic cancer. Dr. Noel will share his current experience of treating patients with eryaspase in combination with chemotherapy in the first-line setting.

    To register for the event, please click here.

    Manuel Hidalgo, M.D., Ph.D., is currently the Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital. Dr. Hidalgo received his M.D. from the University of Navarra in Pamplona, Spain in 1992, and Ph.D. from University Autonoma of Madrid in 1997. He trained in medicine and medical oncology at Hospital "12 de Octubre" in Madrid and at the University of Texas Health Science Center in San Antonio, Texas. He also completed a fellowship program in anticancer drug development at the Institute of Drug Development in San Antonio. Prior to this position, he served as an Assistant Professor of Medicine at the Division of Hematology and Oncology at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns Hopkins University to serve as Director of the Gastrointestinal Oncology Program at the Kimmel Comprehensive Cancer Center, where he also held the title of Associate Professor of Oncology. Dr. Hidalgo became Director of the Clinical Research Program at the Spanish National Cancer Center in 2009 and Vice Director of Translational Research in 2011. In 2015, he became the Chief of the Division of Hematology and Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center in Boston. Dr. Hidalgo also served as the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School. His main focus of research has been new drug development in pancreatic cancer. His group popularized the use of Avatar mouse models for cancer research and recently contributed to the development and Federal Drug Administration (FDA) approval of nab-paclitaxel for pancreatic cancer treatment. Dr. Hidalgo's current research focuses on strategies for personalized medicine and immunotherapy in pancreatic cancer. Dr. Hidalgo also serves on the Board of Directors for Bristol Myers Squibb (BMS).

    Marcus S. Noel, M.D., is a medical oncologist who specializes in the treatment of gastrointestinal cancers. At Georgetown Lombardi Comprehensive Cancer Center, Dr. Noel is Associate Professor of Medicine and Co-Director, Clinical Research Management Office, both within the Division of Hematology and Oncology, Department of Medicine. His research efforts focus on novel drug development for pancreatic cancer. He obtained a Bachelor of Arts degree in biology from Case Western Reserve University and his medical degree from Rutgers Medical School formerly Robert Wood Johnson Medical School. Dr. Noel completed his internal medicine residency and medical oncology fellowship at the University of Rochester Medical Center in 2013. He was recently an assistant professor of medicine at the Wilmot Cancer Institute in Rochester New York.

    About ERYTECH and eryaspase

    ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

    The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells' altered asparagine and glutamine metabolism. Eryaspase is in a Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out final results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial (IST) in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

    Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and treatment of acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase). The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

    ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

    ERYTECH is listed on the Nasdaq Global Select Market in the United States (NASDAQ:ERYP) and on the Euronext regulated market in Paris ((ISIN code: FR0011471135, NASDAQ:ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.        

    For more information, please visit www.erytech.com        

    CONTACTS



    ERYTECH                     

    Eric Soyer

    CFO & COO
    LifeSci Advisors, LLC

    Corey Davis, Ph.D.

    Investor relations



    NewCap

    Mathilde Bohin / Louis-Victor Delouvrier

    Investor relations

    Nicolas Merigeau

    Media relations




    +33 4 78 74 44 38

    investors@erytech.com




    +1 (212) 915 2577

    cdavis@lifesciadvisors.com




    +33 1 44 71 94 94

    erytech@newcap.eu





    Attachment



    Primary Logo

    View Full Article Hide Full Article
  5. Papyrus Therapeutics Inc. is delighted to announce that two new members have joined our Board of Directors, Marc Beer as chairman and Professor James Lorens PhD as an independent director.

    Marc brings more then 30 years of therapeutic development and commercialization experience in biotechnology, pharmaceuticals, device and diagnostics. Marc most recently became Executive Chairman of BioTE Medical, a global leader in Precision and Preventive Medicine focused on hormone development and commercialization of optimized hormones for women and men. Additionally, Marc recently became the non-Executive Chairman of Origami Surgical, a patented portfolio of products engineered to enhance robotic assisted surgery and to improve safety, autonomy and surgical…

    Papyrus Therapeutics Inc. is delighted to announce that two new members have joined our Board of Directors, Marc Beer as chairman and Professor James Lorens PhD as an independent director.

    Marc brings more then 30 years of therapeutic development and commercialization experience in biotechnology, pharmaceuticals, device and diagnostics. Marc most recently became Executive Chairman of BioTE Medical, a global leader in Precision and Preventive Medicine focused on hormone development and commercialization of optimized hormones for women and men. Additionally, Marc recently became the non-Executive Chairman of Origami Surgical, a patented portfolio of products engineered to enhance robotic assisted surgery and to improve safety, autonomy and surgical efficiency.

    Marc founded Renovia Inc., a leading digital therapeutic company focused on women's healthcare. Marc is the former Chief Executive Officer of Aegerion Pharmaceuticals (NASDAQ:AEGR), which he took public in October, 2010. The company successfully launched two rare disease therapeutics. Previously, Marc founded and took public Viacell Inc. (NASDAQ:VIAC)., a leader in cell therapy development and commercialization. Marc sold Viacell to Perkin Elmer (NYSE:PKI) in 2007. Marc was previously the founding Chairman of Erytech Pharma (NASDAQ:ERYP), also founding Chairman of Good Start Genetics (GSG) which was recently acquired by InVitae (NASDAQ:NVTA), and founding Chairman of Minerva (NASDAQ:NERV), which went public in 2013. Prior, Marc held several leadership roles at Genzyme, responsible for the commercial launch of several therapeutic proteins addressing rare disease populations.

    Marc is a member of the Miami University Business Advisory Council and previously a member of the Notre Dame Research and Commercialization Advisory Committee and the Notre Dame Graduate Studies Research and Advisory Council. Marc holds a BS from Miami University (Ohio).

    Professor James [Jim] Lorens has joined as an independent director. Jim is a recognized academic entrepreneur with over 35 years academic research and biotech industry experience from the US and Europe that will bring tremendous insight to the Papyrus Board. Jim was part of the Stanford University research group who spun-out Rigel Pharmaceuticals in South San Francisco in 1997, where he led a multidisciplinary technology innovation team during the start-up phase, and Oncology R&D during later expansion of the company through to NASDAQ listing. He founded BergenBio AS in 2007, a spinout company of the University of Bergen, to facilitate clinical translation of his academic group's pioneering research on the AXL receptor tyrosine kinase and served as their Chief Scientific Officer 2008-2021. BerGenBio took the first AXL targeting agent into the clinic in 2013 and was listed on the Oslo Stock Exchange in 2017 (BGBIO). BerGenBio's AXL inhibitor (bemcentinib) is currently in Phase II clinical trials for the treatment of cancer and Covid-19.

    Jim is Professor in the Department of Biomedicine at the University of Bergen Faculty of Medicine, Norway and principal investigator at the Center for Cancer Biomarkers, Norwegian Center of Excellence. He is also a member of the Norwegian Academy of Sciences and Letters.

    Prof. Lorens has served on several Editorial Boards, government R&D policy commissions and the Norwegian Research Council Boards on Innovation and Health Research.

    CEO Dr Paul Blake stated ‘I am excited to work with these inspiring colleagues. Marc brings tremendous business acumen coupled with his ability to understand the benefits of this innovative science. Jim has a deep understanding of the potential of our work and has had the invaluable and recent experience of creating a company in a related field successfully'.

    About Papyrus Therapeutics Inc.: Papyrus Therapeutics, Inc. (West Chester, PA, USA) is an emerging biopharma company developing novel tumor suppressor-based therapies. Papyrus´s lead therapeutic is a modified, recombinant version of Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML). OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML can overcome this challenge by reconstituting normal RTK signaling in the tumor.

    www.papyrustherapeutics.com

    View Full Article Hide Full Article
View All Erytech Pharma S.A. News